Jacques Gaudreault

4.2k citations

36 papers · 3.2k indexed · 1 hit paper · h-index 17

Impact in

Ophthalmology top 0.5%
- Retinal Diseases and Treatments
Oncology top 2%
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology

Papers in

Ophthalmology 7
- Retinal Diseases and Treatments 6
- Retinal and Optic Conditions 3
Immunology and Allergy 4
- Cell Adhesion Molecules Research 4

Co-authors: William Novotny Eric Holmgren Lisa A. Damico Fairooz F. Kabbinavar Louis Fehrenbacher John Nemunaitis David M. Jablons Corey J. Langer
Journals: Investigative Ophthalmology & Visual Science (8 papers)Journal of Clinical Oncology (7 papers)Pharmaceutical Research (4 papers)Clinical Pharmacology & Therapeutics (2 papers)Journal of Cardiovascular Pharmacology (2 papers)
Partner nations: United States Switzerland Canada

In The Last Decade

Jacques Gaudreault

35 papers receiving 3.1k citations

Hit Papers

align trajectories log scale

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer 2004 · 1.5k citations

Peers

Countries citing papers authored by Jacques Gaudreault

Since Specialization

Citations

This map shows the geographic impact of Jacques Gaudreault's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacques Gaudreault with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacques Gaudreault more than expected).

Fields of papers citing papers by Jacques Gaudreault

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacques Gaudreault. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacques Gaudreault. The network helps show where Jacques Gaudreault may publish in the future.

Co-authors

The 25 scholars most cited alongside Jacques Gaudreault, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jacques Gaudreault Line = papers co-authored together Jacques Gaudreault links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Preclinical Characterization of XB002, an Anti–Tissue Factor Antibody–Drug Conjugate for the Treatment of Solid Tumors Molecular Cancer Therapeutics ·Seema Kantak, Raffaella Faggioni, Allen G. Cai, Maryam M. Bhatti, Jing Li, Inna Vainshtein, Jackie Cheng, Brian A. Mendelsohn, Jacques Gaudreault, Thi‐Sau Migone, Jan-Willem Theunissen	2024	1
2	Pharmacological control of platelet-leukocyte interactions by the human anti-P-selectin antibody inclacumab – preclinical and clinical studies Thrombosis Research ·Dorothée Kling, Corinne Stucki, Sven Kronenberg, Dietrich Tuerck, Éric Rhéaume, Jean‐Claude Tardif, Jacques Gaudreault, Christophe Schmitt	2013	41
3	Preclinical Pharmacology and Safety of ESBA1008, a Single-chain Antibody Fragment, Investigated as Potential Treatment for Age Related Macular Degeneration Investigative Ophthalmology & Visual Science ·Jacques Gaudreault, Tea Gunde, Heather S. Floyd, Joel Ellis, Julia Tietz, Daniela Binggeli, Barbara C. Keller, Anne Schmidt, Dominik Escher	2012	34
4	Clinical pharmacokinetics of bevacizumab in patients with solid tumors Cancer Chemotherapy and Pharmacology ·Jianfeng Lü, René Bruno, Steve Eppler, William Novotny, Bert L. Lum, Jacques Gaudreault	2008	278
5	Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo Experimental Eye Research ·John R. Lowe, James Araujo, Jihong Yang, M. Reich, Amy Oldendorp, Vanessa Shiu, Valerie Quarmby, Henry B. Lowman, Samantha Lien, Jacques Gaudreault, Maurício Maia	2007	135
6	Clinical Pharmacokinetics of Ranibizumab (LucentisTM) in Subjects With AMD Investigative Ophthalmology & Visual Science ·Peter C. Haughney, John R. Lowe, A. Kearns, Jeriza Rusit, Shreeti Lakhani, Lisa A. Damico, Lin Xu, Jacques Gaudreault	2005	7
7	A Pharmacokinetic Model Describing Ocular And Systemic Disposition Of Ranibizumab In Rabbits Investigative Ophthalmology & Visual Science ·Jacques Gaudreault, Lisa A. Damico, Peter C. Haughney, M. Reich, Jeriza Rusit, B.B. Bender	2004	2
8	Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Journal of Clinical Oncology ·David H. Johnson, Louis Fehrenbacher, William Novotny, Roy S. Herbst, John Nemunaitis, David M. Jablons, Corey J. Langer, Russell F. DeVore, Jacques Gaudreault, Lisa A. Damico, Eric Holmgren, Fairooz F. Kabbinavar Hit paper breakdown →	2004	1516
9	Pharmacokinetic study of ranibizumab (LucentisTM) following subconjunctival, intracameral and intravitreal administration in rabbits Investigative Ophthalmology & Visual Science ·Lisa A. Damico, Jacques Gaudreault, Brendan C. Bender, Jeriza Rusit, M. Reich, Amy Oldendorp, Peter C. Haughney	2004	1
10	RhuFab V2 Inhibits VEGF-Isoforms-Stimulated HUVEC Proliferation Investigative Ophthalmology & Visual Science ·John R. Lowe, João R. Araújo, Michele De Palma, Y. Wang, Jacques Gaudreault, Jihong Yang, Ning Yu, D. Fei	2003	3
11	Ocular Pharmacokinetics and Antipermeability Effect of rhuFab V2 in Animals Investigative Ophthalmology & Visual Science ·Jacques Gaudreault, M. Reich, Andrea X. Arata, Jeriza Rusit, N. Pelletier, Vanessa Shiu	2003	1
12	Design, Construction, and In Vitro Analyses of Multivalent Antibodies The Journal of Immunology ·K.F. Miller, Gloria Meng, Jun Liu, Amy Hurst, Vanessa Hsei, W L Wong, Rene Ekert, David A. Lawrence, Steven W. Sherwood, Laura DeForge, Jacques Gaudreault, Gilbert A. Keller, Mark X. Sliwkowski, Avi Ashkenazi, Leonard G. Presta	2003	41
13	Vitreal Pharmacokinetics of rhuFab V2 in Rabbits Using a Non-invasive Method Investigative Ophthalmology & Visual Science ·Jacques Gaudreault, Enrique Escandón, Masayuki Maruoka, M. Reich, D Li, Vanessa Hsei	2002	1
14	Complexation of VEGF with Bevacizumab Decreases VEGF Clearance in Rats Pharmaceutical Research ·Vanessa Hsei, Geralyn G. DeGuzman, Allison Nixon, Jacques Gaudreault	2002	33
15	Mixed-effects modeling of the pharmacodynamic response to the calcimimetic agent R–568 Clinical Pharmacology & Therapeutics ·R L Lalonde, Jacques Gaudreault, David Karhu, Thomas B. Marriott	1999	17
16	Truncated Area Under the Curve as a Measure of Relative Extent of Bioavailability: Evaluation Using Experimental Data and Monte Carlo Simulations Pharmaceutical Research ·Jacques Gaudreault, Diane Potvin, Jean Lavigne, Richard L. Lalonde	1998	19
17	Anticonvulsant Pharmacodynamics and Disposition of Triazolam in Rats††These results were presented, in part, at the Seventh Annual Meeting of the American Association of Pharmaceutical Scientists, San Antonio, TX, November 1992. Journal of Pharmaceutical Sciences ·Jacques Gaudreault, France Varin, Gary M. Pollack	1996	11
18	Population Pharmacokinetics of Terfenadine Pharmaceutical Research ·Richard L. Lalonde, D. Lessard, Jacques Gaudreault	1996	25
19	Pharmacokinetics and Anticonvulsant Effect of a New Hypnotic, CL 284,846, in Rats Pharmaceutical Research ·Jacques Gaudreault, France Varin, Gary M. Pollack	1995	12
20	A Placebo‐Controlled Evaluation of Single, Escalating Doses of CL 284,846, a Non‐Benzodiazepine Hypnotic The Journal of Clinical Pharmacology ·Bernard Beer, John R. Ieni, Wenhui Wu, Donald E. Clody, Peter Amorusi, James Q. Rose, Time Mant, Jacques Gaudreault, Allen Cato, Warren C. Stern	1994	70

About Jacques Gaudreault

Jacques Gaudreault is a scholar working on Ophthalmology, Immunology and Allergy, Nephrology, Oncology and Pulmonary and Respiratory Medicine, having authored 36 papers that have together received 3.2k indexed citations. Recurring topics across this work include Retinal Diseases and Treatments (6 papers), Cancer Treatment and Pharmacology (5 papers), Colorectal Cancer Treatments and Studies (5 papers), Cell Adhesion Molecules Research (4 papers), Angiogenesis and VEGF in Cancer (4 papers), Pharmaceutical studies and practices (3 papers), Retinal and Optic Conditions (3 papers) and Neuroscience and Neuropharmacology Research (3 papers). The work is most often cited by research in Ophthalmology (678 citations), Oncology (1.4k citations), Pulmonary and Respiratory Medicine (1.2k citations), Cancer Research (467 citations) and Radiology, Nuclear Medicine and Imaging (699 citations). Jacques Gaudreault has collaborated with scholars based in United States, Switzerland and Canada. Frequent co-authors include William Novotny, Eric Holmgren, Lisa A. Damico, Fairooz F. Kabbinavar, Louis Fehrenbacher, John Nemunaitis, David M. Jablons, Corey J. Langer, David H. Johnson and Roy S. Herbst. Their work appears in journals such as Investigative Ophthalmology & Visual Science, Journal of Clinical Oncology, Pharmaceutical Research, Clinical Pharmacology & Therapeutics and Journal of Cardiovascular Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact